Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tenofovir Disoproxil Fumarate

FDA-approved product (tablet, oral), marketed as Tenofovir Disoproxil Fumarate, Viread.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Tenofovir Disoproxil Fumarate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic hepatitis B virus infection
  • Hepatitis B virus infection
  • HIV infection
  • HIV-1 infection
  • Infection
  • Liver disease
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Nucleoside and nucleotide reverse transcriptase inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AF07

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA30.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli40.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae26.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis53.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Tenofovir Disoproxil Fumarate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tenofovir Disoproxil Fumarate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Carvedilol for Prevention of Esophageal Varices Progression

    NCT03736265 · start 2017-10-09

    Registered record
    Registry ID
    NCT03736265
    Conditions
    Cirrhosis, Liver; Portal Hypertension
    Interventions
    Carvedilol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2017-10-09
    Completion
    2022-12-30
    Enrolment
    240

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCirrhosis, Liver; Portal Hypertension
    InterventionCarvedilol
    PhaseNot applicable
    Registry statusUnknown

  • A Study of Switching From Entecavir to Tenofovir Disoproxil Fumarate in Subjects With Chronic Hepatitis B

    NCT03258710 · start 2017-10-02

    Registered record
    Registry ID
    NCT03258710
    Conditions
    Hepatitis B, Chronic
    Interventions
    Tenofovir Disoproxil Fumarate
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2017-10-02
    Completion
    2019-11-25
    Enrolment
    75

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B, Chronic
    InterventionTenofovir Disoproxil Fumarate
    PhasePhase 4
    Registry statusCompleted

  • PK and PD Study of Oral F/TAF for HIV Prevention

    NCT02904369 · start 2016-10-06

    Registered record
    Registry ID
    NCT02904369
    Conditions
    HIV
    Interventions
    Emtricitabine; Tenofovir alafenamide; Tenofovir disoproxil
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-10-06
    Completion
    2017-11-21
    Enrolment
    73

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionEmtricitabine; Tenofovir alafenamide; Tenofovir disoproxil
    PhasePhase 1
    Registry statusCompleted

  • Efficacy and Safety of a Dolutegravir-based Regimen for the Initial Management of HIV Infected Adults in Resource-limited Settings

    NCT02777229 · start 2016-07

    Registered record
    Registry ID
    NCT02777229
    Conditions
    HIV-1 Infection
    Interventions
    Dolutegravir 50 mg; Tenofovir disoproxil fumarate 300 mg / lamivudine 300 mg; Efavirenz 400 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-07
    Completion
    2021-07
    Enrolment
    616

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionDolutegravir 50 mg; Tenofovir disoproxil fumarate 300 mg / lamivudine 300 mg; Efavirenz 400 mg
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy of Switching to a FDC of B/F/TAF From E/C/F/TAF, E/C/F/TDF, or ATV+RTV+FTC/TDF in Virologically Suppressed HIV-1 Infected Women

    NCT02652624 · start 2016-02-19

    Registered record
    Registry ID
    NCT02652624
    Conditions
    HIV-1 Infection
    Interventions
    E/C/F/TAF; E/C/F/TDF; ATV; RTV; FTC/TDF; B/F/TAF
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-02-19
    Completion
    2018-11-26
    Enrolment
    472

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionE/C/F/TAF; E/C/F/TDF; ATV; RTV +2 more
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy of Switching From Regimens of ABC/3TC + a 3rd Agent to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV 1 Infected Adults

    NCT02605954 · start 2015-11-18

    Registered record
    Registry ID
    NCT02605954
    Conditions
    HIV-1 Infection
    Interventions
    E/C/F/TAF; ABC/3TC; Third Antiretroviral Agent
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-11-18
    Completion
    2018-01-24
    Enrolment
    275

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-1 Infection
    InterventionE/C/F/TAF; ABC/3TC; Third Antiretroviral Agent
    PhasePhase 3
    Registry statusCompleted

  • Utilization and Efficacy of Tenofovir DF in Adolescents With Chronic Hepatitis B Virus Infection

    NCT02479880 · start 2015-07-03

    Registered record
    Registry ID
    NCT02479880
    Conditions
    Hepatitis B
    Interventions
    Tenofovir DF; DEXA Scan
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2015-07-03
    Completion
    2018-04-11
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B
    InterventionTenofovir DF; DEXA Scan
    PhasePhase 4
    Registry statusTerminated

  • Comprehensive HIV Prevention Package for MSM in Port Elizabeth

    NCT02449733 · start 2015-05

    Registered record
    Registry ID
    NCT02449733
    Conditions
    HIV
    Interventions
    Condom choices; Condom-compatible lubricant choices; Couples HIV counseling and testing (CVCT); Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF); HIV Testing; Linkage to care; Post-exposure prophylaxis (PEP); Risk-reduction counseling
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2015-05
    Completion
    2017-03
    Enrolment
    101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionCondom choices; Condom-compatible lubricant choices; Couples HIV counseling and testing (CVCT); Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) +4 more
    PhaseNot applicable
    Registry statusCompleted

  • Renal Integrase Study

    NCT02351908 · start 2015-03

    Registered record
    Registry ID
    NCT02351908
    Conditions
    HIV
    Interventions
    Stribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat); Isentress® (Raltegravir 400 mg)1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tablet; Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2015-03
    Completion
    2017-04
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionStribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat); Isentress® (Raltegravir 400 mg)1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tablet; Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir)
    PhasePhase 4
    Registry statusCompleted

  • Treatment of Hepatitis B in Resource-limited Settings - a Pilot Program in East Africa

    NCT02344498 · start 2015-01

    Registered record
    Registry ID
    NCT02344498
    Conditions
    Hepatitis B
    Interventions
    Tenofovir disoproxil
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2015-01
    Completion
    2026-12
    Enrolment
    7,350

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHepatitis B
    InterventionTenofovir disoproxil
    PhaseNot recorded
    Registry statusActive not recruiting

  • PRe-Exposure Prophylaxis Acceptability & Readiness Assessments for Toronto gaY, Bisexual and Other Men Who Have Sex With Men-5

    NCT02149888 · start 2014-10

    Registered record
    Registry ID
    NCT02149888
    Conditions
    HIV; Human Immunodeficiency Virus
    Interventions
    Tenofovir/emtricitabine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-10
    Completion
    2016-06
    Enrolment
    52

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; Human Immunodeficiency Virus
    InterventionTenofovir/emtricitabine
    PhasePhase 4
    Registry statusCompleted

  • Study to Evaluate Darunavir/Ritonavir + Lamivudine Versus Continuing With Darunavir/Ritonavir + Tenofovir/Emtricitabine or Abacavir/Lamivudine in HIV Infected Subject

    NCT02159599 · start 2014-07

    Registered record
    Registry ID
    NCT02159599
    Conditions
    HIV Infection
    Interventions
    Darunavir/Ritonavir; Lamivudine; Emtricitabine/tenofovir or abacavir/lamivudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-07
    Completion
    2016-04
    Enrolment
    249

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionDarunavir/Ritonavir; Lamivudine; Emtricitabine/tenofovir or abacavir/lamivudine
    PhasePhase 4
    Registry statusCompleted

  • Switch From Nevirapine-based Regimen to Once a Day Rilpivirine/Emtricitabine/Tenofovir

    NCT02104700 · start 2014-04

    Registered record
    Registry ID
    NCT02104700
    Conditions
    HIV
    Interventions
    Rilpivirine/Emtricitabine/Tenofovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2014-04
    Completion
    2016-07
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    InterventionRilpivirine/Emtricitabine/Tenofovir
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • A Pharmacokinetic Evaluation of Levonorgestrel Implant and Antiretroviral Therapy

    NCT01789879 · start 2014-03-04

    Registered record
    Registry ID
    NCT01789879
    Conditions
    HIV; Contraception
    Interventions
    Levonorgestrel; Nevirapine; Efavirenz
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-03-04
    Completion
    2015-03-04
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV; Contraception
    InterventionLevonorgestrel; Nevirapine; Efavirenz
    PhasePhase 2
    Registry statusCompleted

  • Safety and Efficacy of GS-4774 for the Treatment of Chronic Hepatitis B

    NCT01943799 · start 2013-09-13

    Registered record
    Registry ID
    NCT01943799
    Conditions
    Chronic HBV Infection
    Interventions
    GS-4774; OAV Regimen
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2013-09-13
    Completion
    2015-03-03
    Enrolment
    178

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic HBV Infection
    InterventionGS-4774; OAV Regimen
    PhasePhase 2
    Registry statusCompleted